{"article_title": "Amgen Calls For Halt To Neulasta Biosimilar Marketing", "article_keywords": ["sued", "halt", "calls", "federal", "marketing", "violated", "apotex", "amgen", "neulasta", "york", "white", "biosimilar", "view"], "article_url": "http://www.law360.com/articles/715824/amgen-calls-for-halt-to-neulasta-biosimilar-marketing", "article_text": "Amgen Calls For Halt To Neulasta Biosimilar Marketing\n\nLaw360, New York (October 19, 2015, 6:16 PM ET) -- Amgen Inc. asked a Florida federal court Friday to stop Canadian generics maker Apotex Inc. from marketing its biosimilar copy of the blockbuster biologic Neulasta until it complies with a federal law requiring it to give Amgen proper notice.\n\n\n\nAmgen had sued Apotex in August over its proposed biosimilar to Neulasta, a drug that helps reduce the infection risk in people with non-bone-marrow-related cancers and low white blood cell counts as a result of chemotherapy, alleging it violated two patents.\n\n\n\nApotex hit back on Oct. 6...\n\nTo view the full article, register now.", "article_metadata": {"description": "Amgen Inc. asked a Florida federal court Friday to stop Canadian generics maker Apotex Inc. from marketing its biosimilar copy of the blockbuster biologic Neulasta until it complies with a federal law requiring it to give Amgen proper notice.", "apple-itunes-app": "app-id=934560389, app-argument=law360://www.law360.com/articles/715824/amgen-calls-for-halt-to-neulasta-biosimilar-marketing", "csrf-token": "FxQAZnkvEgTCatJWFaTS1acm/yl7Dht9/03gIEE+7GlMf7EfmN7E3fg9bF6YsnxBXzwH02cmJGIu+RODf380Zw==", "csrf-param": "authenticity_token", "og": {"url": "http://www.law360.com/articles/715824/amgen-calls-for-halt-to-neulasta-biosimilar-marketing", "image": "https://www.law360.com/images/360.png", "type": "website", "title": "Amgen Calls For Halt To Neulasta Biosimilar Marketing - Law360"}, "viewport": "width=device-width, initial-scale=1.0"}, "_id": "\"57477af46914bd0286fe29b4\"", "article_summary": "Amgen Calls For Halt To Neulasta Biosimilar MarketingLaw360, New York (October 19, 2015, 6:16 PM ET) -- Amgen Inc. asked a Florida federal court Friday to stop Canadian generics maker Apotex Inc. from marketing its biosimilar copy of the blockbuster biologic Neulasta until it complies with a federal law requiring it to give Amgen proper notice.\nAmgen had sued Apotex in August over its proposed biosimilar to Neulasta, a drug that helps reduce the infection risk in people with non-bone-marrow-related cancers and low white blood cell counts as a result of chemotherapy, alleging it violated two patents.\nApotex hit back on Oct. 6...To view the full article, register now."}